Professional Supply API CAS 129101-54-8 Rivastigmine Tartrate

• Powder: Yes
• Customized: Non-Customized
• Certification: GMP, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Solid
• Purity: >99%
• Model NO.: TY-02ALI
• CAS No.: 129101-54-8
• Appearance: White Powder
• Einecs: 616-396-9
• Assay: 99%
• Shelf: 2 Years
• Transport Package: 25kg/Drum 1kg, 10kg, 100kg, 200kg
• Specification: 25kg/drum
• Trademark: tongyon
• Origin: China
• Production Capacity: 5000kg/Month

Product Description

 

Product name	Rivastigmine tartrate
CAS	129101-54-8
Appearance	white powder
Assay	99%
Storage	Cool and Protect from light

Product Name:Rivastigmine tartrate
CAS:129101-54-8
MF:C18H28N2O8
MW:400.42
EINECS:603-318-3
Mol File:129101-54-8.mol  
Melting point:123-1250C
alpha D20 +4.7° (c = 5 in ethanol)
storage temp. -20°C Freezer
solubility H2O: soluble15mg/mL, clear
form powder
color white to beige





Rivastigmine tartrate is rivastigmine Alzheimer's disease drugs, rivastigmine is physostigmine derivative by Novartis for the first time successfully developed the trade name Exelon (exelon), a molecule with there carbamate structure, is a kind of amino acid of selective cerebral cholinesterase inhibitor, can also inhibit the acetylcholinesterase and butyrylcholinesterase, cholinergic neurons by delaying the release of acetylcholine degradation and energy promoting cholinergic nerve conduction, can improve cognitive function disorders mediated by cholinergic, thereby improving the cognitive function of Alzheimer's disease patients. Rivastigmine plasma protein binding is weak, easily through the blood-brain barrier, which has a high degree of brain selectivity. It not only selectively acts on the most easily affected cerebral cortex and hippocampus, but also preferentially inhibits the dominant subtype of AChE in the brain, resulting in a reduction in the efficacy of peripheral cholinergic side effects. Rivastigmine in vivo half-life is short and long duration of action. Unlike tacrine, this product in the hippocampus and cortex of G1 enzyme inhibitory effect is stronger. Clinic for the treatment of mild to moderate Alzheimer-type dementia, or Alzheimer's disease can be suspected Alzheimer's disease clinically.

GuangZhou TongYi biochemistry technology Co., Ltd is a company specializing in active pharmaceutical ingredient
(API), biology, plant extracts, chemical raw materials, fine chemicals, pharmaceutical intermediates, cosmetics raw
material. Our company has always adhered to the company philosophy of integrity, professionalism, quality first, and
customer service. With the efforts of all the company's employees, it has established long-term
and stable cooperative relations with many domestic and foreign customers, and won the unanimous trust of domestic
and foreign customers. With good comments, our company have made great progress.

Our company takes pioneering and innovative, high-quality and efficient as the code of conduct, and strives to provide
customers with efficient services,
high-quality products, and reasonable prices. We have established a customer demand-oriented, flexible, diverse and customizable service according to the different needs of different customers. Mode, and ultimately achieve the goal of
win-win.

Our company focuses on the future and the world, and will continue to devote itself to technological progress and the
development of new products in the future, hoping to work hand in hand with new and old friends at home and abroad
to create a better future.